News Discover the latest news stories, blog posts and publications from Cobra's expert team. You are here: Home News Toggle filters Year: All Years 2019 2018 2017 2016 2015 2014 2013 2012 2011 or Month: All Months January February March April May June July August September October November December or Type: All Categories DNA Fill Finish General DNA Proteins Technologies Viral Vectors Cobra and The University of Manchester Receive £217K Innovate UK / BBSRC Funding Awarded as part of £20M competition bringing innovative biotechnology projects to market BLOG: Disposable Solutions 2015 Tony Hitchcock's Pharma IQ Blog 2014 Highlights What a year 2014 has been! We've put together a brief round up of the highlights from Cobra... BLOG: If Single Use is Now the Norm Tony Hitchcock's Pharma IQ Blog BLOG: Where Next for Single Use Systems? Tony Hitchcock's Pharma IQ Blog Cobra Biologics and QuiaPEG Announce Strategic Collaboration Offering a Novel PEGylation Technology Platform Strategic alliance focused on the processing of biological drugs using a novel PEGylation platform. KUSBP Tenant Grows from One Office to Multinational Company Keele University Science & Business Park: Business Success Story Cobra Biologics Appoints CSO Cobra announces the appointment of Dr. Daniel C. Smith as Chief Scientific Officer Cobra Biologics Granted Approval for Research Tax Credit Cobra is pleased to announce that the French Ministry of Higher Education & Research (MESR) has recognised the CMO as an approved service provider for antibody & recombinant protei... Manufacturing Oncology Products: A Guide to Outsourcing Success UKTI Japan Life Sciences Mission for Oncology Cobra Biologics and BioCancell Announce Agreement to Manufacture Promising Cancer Therapy Drug DNA Cobra Biologics and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials. Pagination Go to Previous page Go to page 6 Go to page 7 Go to page 8 Go to page 9
Cobra and The University of Manchester Receive £217K Innovate UK / BBSRC Funding Awarded as part of £20M competition bringing innovative biotechnology projects to market
2014 Highlights What a year 2014 has been! We've put together a brief round up of the highlights from Cobra...
Cobra Biologics and QuiaPEG Announce Strategic Collaboration Offering a Novel PEGylation Technology Platform Strategic alliance focused on the processing of biological drugs using a novel PEGylation platform.
KUSBP Tenant Grows from One Office to Multinational Company Keele University Science & Business Park: Business Success Story
Cobra Biologics Appoints CSO Cobra announces the appointment of Dr. Daniel C. Smith as Chief Scientific Officer
Cobra Biologics Granted Approval for Research Tax Credit Cobra is pleased to announce that the French Ministry of Higher Education & Research (MESR) has recognised the CMO as an approved service provider for antibody & recombinant protei...
Manufacturing Oncology Products: A Guide to Outsourcing Success UKTI Japan Life Sciences Mission for Oncology
Cobra Biologics and BioCancell Announce Agreement to Manufacture Promising Cancer Therapy Drug DNA Cobra Biologics and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.